Table 2. Ongoing/completed phase-II clinical trial for COVID-19 vaccines.
| Sl. No. | Clinical trial ID | Study start date and end date (probable) | No. of patients enrolled in this clinical trial | Randomized | Developer | Country of origin | Vaccine type | Current status | Remark |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04405076 | May 29, 2020 and August 2021 | 600 | Yes | ModernaTX, Inc | United States | mRNA | Not recruiting | Study was performed for dose-confirmation and accessed the safety |
| 2 | NCT04470609 | July 10, 2020 and November 2021 | 471 | Yes | Chinese Academy of Medical Sciences | China | Inactivated type of vaccine | Enrolling by invitation | This trial evaluate the immunogenicity and doses |
| 3 | NCT04412538 | May 15, 2020 and September 2021 | 942 | Yes | Chinese Academy of Medical Sciences | China | Inactivated type of vaccine | Recruiting | In this study healthy volunteers (18 to 59 years) was chosen to understand the immunogenicity |
| 4 | NCT04276896 | March 24, 2020 and December 31, 2024 | 100 | No | Shenzhen Geno-Immune Medical Institute | China | Synthetic Minigene vaccine | Recruiting | This vaccine contains viral structural proteins etc. |
| 5 | NCT04437875 | June 17, 2020 and August 10, 2020 | 38 | No | Gamaleya Research Institute of Epidemiology and Microbiology | Russian Federation | Lyophilisate solution | Completed | Gam-COVID-vaccine lyophilisate to open study of safety, tolerability and immunogenicity |
| 6 | NCT04473690 | December 20, 2020 and March 23, 2024 | 180 | Yes | Kentucky BioProcessing, Inc. | United States | KBP vaccine | Not yet recruiting | Adult subjects of different age group was accessed and evaluated immunogenicity and safety |
| 7 | NCT04445389 | June 17, 2020 and June 17, 2022 | 210 | Yes | Genexine, Inc. | Korea, Republic of | DNA vaccine | Recruiting | This DNA vaccine was used to understand the immunogenicity and tolerability among 150 healthy volunteers |
| 8 | NCT04380532 | May 15, 2020 and June 15, 2021 | 20 | No | Immunitor LLC | Canada | Tableted thermostable vaccine | Not recruiting | Tableted vaccine developed from pooled plasma of COVID-19 patients |
| 9 | NCT04341389 | April 12, 2020 and January 31, 2021 | 508 | Yes | Insitute of Biotechnology, Academy of Military Medical Sciences | China | Ad5 vector (Ad5-nCoV) | Not recruiting | In this study Ad5-nCoV was accessed among 508 healthy volunteers |
| 10 | NCT04386252 | February 2021 and February 2022 | 175 | Yes | Aivita Biomedical, Inc. | United States | DC vaccine | Not yet recruiting | Antigens combined with autologous DCs is the combination of this vaccine |
| 11 | NCT04324606 | April 23, 2020 and October 2021 | 1,090 | Yes | University of Oxford | United Kingdom | ChAdOx1 nCoV-19 | Not recruiting | This study accessed the immunogenicity and safety |
| 12 | NCT04398147 | August 1, 2020 and December 30, 2021 | 696 | Yes | CanSino Biologics Inc. | Canada | Recombinant nCoV (Ad5 vector) vaccine | Not yet recruiting | To understand the safety, tolerability of Ad5-nCoV |
| 13 | NCT04471519 | July 13, 2020 and June 30, 2021 | 755 | Yes | Bharat Biotech International Limited | India | Whole-Virion inactivated type vaccine | Recruiting | BBV152 vaccine formulations was access in 3 investigational subgroups |
| 14 | NCT04463472 | June 29, 2020 and July 31, 2021 | 30 | No | AnGes, Inc. | Japan | DNA vaccine | Recruiting | Study to assess safety and immunogenicity of 2 doses of IM AG0301-COVID-19 |
| 15 | NCT04444674 | June 24, 2020 and December 2021 | 2,130 | Yes | University of Witwatersrand | South Africa | ChAdOx1 nCoV-19 | Recruiting | This study accessed the immunogenicity and safety of adults aged 18–65 years living with and without HIV |
| 16 | NCT04380701 | April 23, 2020 and November 2020 | 456 | No | BioNTech RNA Pharmaceuticals GmbH | Germany | RNA vaccine | Recruiting | This RNA vaccine evaluate the immunogenicity and safety |
| 17 | NCT04480957 | August 4, 2020 and January 2021 | 92 | Yes | Arcturus Therapeutics, Inc. | Singapore | Self-replicating (replicon) mRNA formulated in a LNP | Not yet recruiting | Safety and tolerability and immungenicity of investigational vaccine ARCT-021 |
| 18 | NCT04400838 | May 28, 2020 and September 2021 | 12,390 | Yes | University of Oxford | United Kingdom | ChAdOx1 nCoV-19 | Recruiting | Phase-II/phase-III study to evaluate the immunogenicity of 12,330 volunteers |
| 19 | NCT04368728 | April 29, 2020 and January 29, 2023 | 43,998 | Yes | BioNTech SE | United States | RNA vaccine (BNT162) | Recruiting | Evaluate the safety and immunogenicity of this vaccine (BNT162) |
| 20 | NCT04324606 | April 23, 2020 and October 2021 | 1,090 | Yes | University of Oxford | United Kingdom | Adenovirus-vectored vaccine (COV001) | Not recruiting | This vaccine (COV001) was used among contain 1,090 volunteers to understand the immunogenicity |
| 21 | NCT04368988 | May 25, 2020 and November 18, 2021 | 1,419 | Yes | Novavax, Inc. | Australia | Nanoparticle based vaccine contains recombinant S protein | Recruiting | Evaluate the immunogenicity of this vaccine with/without matrix-M adjuvant |
| 22 | NCT04447781 | July 15, 2020 and February 22, 2022 | 160 | Yes | Inovio Pharmaceuticals | United States | DNA based | Recruiting | Vaccine (plasmid pGX9501), which encodes for the full length of the Spike glycoprotein of SARS-CoV-2 to determine the immunogenicity |
| 23 | NCT04515147 | September 28, 2020 and November 9, 2021 | 660 | Yes | CureVac AG | Germany | mRNA vaccine | Recruiting | mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response |
Information has been taken from: https://ClinicalTrials.gov, EU Clinical Trials Register, Chinese Clinical Trial Register.
All information about the table was accessed on 30 November 2020.